

# CytoDyn Inc.

14:41 28 Jan 2020

## CytoDyn set to explore lead drug leronlimab to combat killer Coronavirus

CytoDyn Inc (OTCMKTS:CYDY) told investors it was looking for potential partners to study its lead drug leronlimab for treating the spreading killer coronavirus, which broke out in China and has now claimed 106 lives.

Coronavirus is the name for a large family of viruses, some causing illness in people and others that circulate in animals. The 2019 Novel Coronavirus (2019-nCoV) has been identified as the cause of an outbreak of the respiratory illness first detected in the city of Wuhan in China.

### Potential global emergency

The virus is rapidly becoming a potential global emergency and the number of cases of those infected has now surged to 4,515 yesterday from 2,835 the previous day.

Leronlimab is an antibody targeting the CCR5 receptor. It has the potential for multiple therapeutic uses.

The candidate has shown no drug-related serious adverse events in nine clinical trials with more than 800 patients, and has been previously used in combination with protease inhibitors in HIV therapy, which could be potentially used to treat the specific strain of the 2019-nCoV.

"Leronlimab has both the potential to enhance the cellular immune response by suppressing Treg cells that, in turn, inhibit the anti-viral T-cell responses and the potential to repolarize macrophage activity," said Dr Bruce Patterson, CEO and founder of IncellDx, CytoDyn's diagnostic partner and an advisor to CytoDyn.

### Contributing factor

"Lung (alveolar) macrophages in coronavirus infections have been implicated as a contributing factor to significant morbidity and mortality of the infectious disease. Leronlimab could potentially synergize with other retroviral therapies that [are] currently being used for the potential treatment of 2019-nCoV."

CytoDyn CEO Nader Pourhassan added: "We support efforts to identify new and potential treatments to limit the spread of the 2019-nCoV, which is affecting people on a global scale at an accelerating rate. We look forward to advancing discussions with potential partners to study leronlimab as a treatment option for this deadly virus."

CytoDyn shares in New York advanced 6.55% to US\$1.22 on Tuesday and yesterday gained 5.53%.

---Updates for share price---

Contact the author at giles@proactiveinvestors.com

**Price:** 2.85

**Market Cap:** \$1.37 billion

### 1 Year Share Price Graph



June 2019 November 2019 June 2020

### Share Information

**Code:** CYDY

**Listing:** OTCQB

<b>52 week</b>	<b>High</b>	<b>Low</b>
	<b>3.84</b>	<b>0.261</b>

**Sector:** Pharma & Biotech

**Website:** www.cytodyn.com

### Company Synopsis:

*CytoDyn is a biotechnology company focused on the clinical development and potential commercialization of humanized monoclonal antibodies for the treatment and prevention of Human Immunodeficiency Virus (HIV) infection. The Company has one of the leading monoclonal antibodies under development for HIV infection, PRO 140, which has finished Phase 2 clinical trials with demonstrated antiviral activity in man.*

action@proactiveinvestors.com

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts, journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Contact us +44 (0)207 989 0813 [action@proactiveinvestors.com](mailto:action@proactiveinvestors.com)

### No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Content on the Site is provided for information purposes only, and none of the information contained on the Site constitutes an offer, solicitation or recommendation to buy or sell a security. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume which any Content on the Site may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, suitability or profitability of any particular security, portfolio of securities, transaction, investment, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including Company-related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

The Site does not, and is not intended to, provide investment, tax, accounting, legal or insurance advice, and is not and should not be construed as providing any of the foregoing. You should consult an attorney or other relevant professional regarding your specific legal, tax, investment or other needs as tailored to your specific situation.

In exchange for publishing services rendered by the Company on behalf of CytoDyn Inc. named herein, including the promotion by the Company of CytoDyn Inc. in any Content on the Site, the Company receives from said issuer annual aggregate cash compensation in the amount up to Twenty Five Thousand (\$25,000).